Skip Navigation LinksHome > March 2014 - Volume 57 - Issue 1 > Maternal Serum Analyte Screening for Fetal Aneuploidy
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0000000000000017
Noninvasive Screening for Fetal Aneuploidies: Eliminating Unwanted Surprises

Maternal Serum Analyte Screening for Fetal Aneuploidy


Collapse Box


In the first and second trimesters, chemicals produced by the fetoplacental unit are measured to assess risks of fetal abnormalities. Consistent associations between levels of these proteins in such pregnancies enable these biomarkers to be used to calculate risk for Down syndrome and other chromosomal abnormalities in individual pregnancies. Special consideration may be required when assessing risk in multiple pregnancies and pregnancies achieved with infertility therapy.

© 2014 by Lippincott Williams & Wilkins.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.